Agendia Appoints VP of Business Development



    
    Strategic Position Created to Increase Pharmaceutical & Biotechnology
    Partnerships
    

    HUNTINGTON BEACH, CA and AMSTERDAM, The Netherlands, Feb. 11 /CNW/ -
Agendia, a world leader in molecular cancer diagnostics, today announced the
appointment of Alan B. Carter as the company's new Vice President of Global
Business Development.
    "As we continue to grow as a global company, Alan's appointment furthers
one of our primary aims," commented Dr. Bernhard Sixt, Ph.D., President and
Chief Executive Officer. "His extensive business development expertise will
strengthen our ongoing programs and pipeline projects and also allows us to
capitalize on our genomics platform in close collaboration with biotechnology
and pharmaceutical partners. With Alan's involvement, Agendia will continue to
play a central role in making targeted therapies one of the cornerstones of
personalized medicine."
    Mr. Carter brings 25 years of business development, sales and marketing
experience from a number of top tier life sciences companies such as BioTrove,
Celera, Applied Biosystems and Perkin Elmer. At Agendia, Mr. Carter will
assume responsibility for strategic business opportunities to build on the
current success of Agendia's molecular diagnostics portfolio. This products
suite includes MammaPrint(R), the only FDA approved test for rapidly and
accurately diagnosing therapeutic options for breast cancer patients.
Additionally, he will play an important role in forging Agendia's strategic
alliances with pharmaceutical and biotech companies to accelerate the use of
molecular diagnostics in drug development, companion diagnostics and safety
testing programs.

    About Agendia

    Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatments within reach of
patients. Building on a cutting edge genomics platform for tumor gene
expression profiling, the company's tests aim to help physicians more
accurately tailor cancer treatments. The company markets four products, with
several new genomic tests under development. In addition, Agendia collaborates
with pharmaceutical companies to develop highly effective personalized drugs
in the area of oncology. Agendia was awarded the 2008 North American Oncology
Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia
is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

    For more information please visit http://www.agendia.com.





For further information:

For further information: MEDIA CONTACTS: Hans Herklots, Head of
Corporate Communications, Agendia, +31-20-462-1557 (Office), +31-620-083-509
(Mobile), hans.herklots@agendia.com; Valerie Delva, Account Executive,
Ricochet Public Relations, (212) 679-3300 x131 (Office), (917) 975-3191
(Mobile), vdelva@ricochetpr.com

Organization Profile

AGENDIA BV

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890